Executive SummaryIn biotech's early days, companies thought they could hedge their long-term bets by relatively inexpensive and much shorter-term plays in diagnostics. But finding diagnostics with enough value proved difficult. Now biotechs are at it again, focusing on the diagnostic implications of pharmacogenomics, the science of linking drug efficacy to genes, which can be used to sort out which patients will benefit from particular drugs.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.